Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib DDI Study with CYP3A Inhibitors in B-Cell Malignancies
NCT04551963Phase 1Completed
- Sponsor
- BeiGene
- Start
- Nov 2020
- Primary completion
- Feb 2022
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, open-label trial of zanubrutinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL) and 2 more (2 arms), sponsored by BeiGene. Primary endpoints: Area Under Plasma Concentration-time Curve up to the Last Measurable Concentration, Area Under Plasma Concentration-time Curve From Time 0 Extrapolated to 24 Hours and 3 more. Started Nov 2020; status: completed.
02
Drugs
zanubrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)mantle cell lymphoma (MCL)Waldenstrom macroglobulinemia (WM)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT04551963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04551963.